EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Generative Biology to Evidence-Centric Drug Discovery

Danishuddin, Qazi Mohammad Sajid Jamal, Khurshid Ahmad

Pharmaceuticals · 06.11.2026 · 19 (11) · 1765

DOI: 10.3390/ph19111765 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 06.11.2026. Verfasst von Danishuddin und 2 weiteren Autor:innen. Die Arbeit nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qassim University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Generative and predictive artificial intelligence (AI) is rapidly increasing the number of molecular, structural, cellular, and therapeutic hypotheses that can be explored computationally. Experimental capacity, however, has not expanded at a comparable rate. The result is an evidence bottleneck, in which biological hypotheses are generated faster than they can be experimentally tested, reproduced, and translated. This mismatch is particularly consequential for pharmaceutical discovery, where computational predictions alone cannot establish biological function, mechanism, or therapeutic value. As the number of computationally generated hypotheses grows, the central challenge shifts from candidate generation to the prioritization of hypotheses for experimental validation. This evidence bottleneck represents a defining constraint of AI-enabled biological discovery. We examine how different biological claims, including structural, interaction, functional, mechanistic, and therapeutic claims, require distinct types and levels of evidence. We also address the cost and context-dependence of experimental validation. Furthermore, we discuss how information-guided experimental design and iterative model–experiment feedback can improve the allocation of limited experimental capacity. We propose an evidence-centric framework for drug discovery that extends the evaluation of generative models beyond their ability to generate or rank hypotheses. The framework emphasizes experimental testability, mechanistic understanding, reproducibility, and translation into actionable biological and therapeutic knowledge.

Förderung

  • Qassim University

Zitieren

APA

Danishuddin, Jamal, Q. M. S., & Ahmad, K. (2026). From Generative Biology to Evidence-Centric Drug Discovery. Pharmaceuticals, 19(11), 1765. https://doi.org/10.3390/ph19111765

Vancouver

Danishuddin, Jamal QMS, Ahmad K. From Generative Biology to Evidence-Centric Drug Discovery. Pharmaceuticals. 2026;19(11):1765. doi:10.3390/ph19111765

BibTeX
@article{Danishuddin2026,
  author = {Danishuddin and Jamal, Qazi Mohammad Sajid and Ahmad, Khurshid},
  title = {From Generative Biology to Evidence-Centric Drug Discovery},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1765},
  doi = {10.3390/ph19111765}
}
Kostenlos starten →